tetano
Editor, Senior Moderator
Comput Struct Biotechnol J
. 2020;18:2200-2208.
doi: 10.1016/j.csbj.2020.08.016. Epub 2020 Aug 26.
Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2
Qizhang Li[SUP] 1 2 [/SUP], Zhiying Wang[SUP] 1 2 [/SUP], Qiang Zheng[SUP] 1 2 [/SUP], Sen Liu[SUP] 1 2 [/SUP]
Affiliations
Abstract
In less than eight months, the COVID-19 (coronavirus disease 2019) caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus has resulted in over 20,000,000 confirmed cases and over 700,000 deaths around the world. With the increasing worldwide spreading of this disease, the lack of effective drugs against SARS-CoV-2 infection makes the situation even more dangerous and unpredictable. Although many forces are speeding up to develop prevention and treatment therapeutics, it is unlikely that any de novo drugs will be available in months. Drug repurposing holds the promise to significantly save the time for drug development, since it could use existing clinic drugs to treat new diseases. Based on the "steric-clashes alleviating receptor (SCAR)" strategy developed in our lab recently, we screened the library of clinic and investigational drugs, and identified nine drugs that might be repurposed as covalent inhibitors of the priming proteases (cathepsin B, cathepsin L, and TMPRSS2) of the spike protein of SARS-CoV-2. Among these hits, five are known covalent inhibitors, and one is an anti-virus drug. Therefore, we hope our work would provide rational and timely help for developing anti-SARS-CoV-2 drugs.
Keywords: COVID-19; Covalent inhibitors; Drug repurpose; Drug screening; SCARdock.
. 2020;18:2200-2208.
doi: 10.1016/j.csbj.2020.08.016. Epub 2020 Aug 26.
Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2
Qizhang Li[SUP] 1 2 [/SUP], Zhiying Wang[SUP] 1 2 [/SUP], Qiang Zheng[SUP] 1 2 [/SUP], Sen Liu[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32868983
- PMCID: PMC7448953
- DOI: 10.1016/j.csbj.2020.08.016
Abstract
In less than eight months, the COVID-19 (coronavirus disease 2019) caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus has resulted in over 20,000,000 confirmed cases and over 700,000 deaths around the world. With the increasing worldwide spreading of this disease, the lack of effective drugs against SARS-CoV-2 infection makes the situation even more dangerous and unpredictable. Although many forces are speeding up to develop prevention and treatment therapeutics, it is unlikely that any de novo drugs will be available in months. Drug repurposing holds the promise to significantly save the time for drug development, since it could use existing clinic drugs to treat new diseases. Based on the "steric-clashes alleviating receptor (SCAR)" strategy developed in our lab recently, we screened the library of clinic and investigational drugs, and identified nine drugs that might be repurposed as covalent inhibitors of the priming proteases (cathepsin B, cathepsin L, and TMPRSS2) of the spike protein of SARS-CoV-2. Among these hits, five are known covalent inhibitors, and one is an anti-virus drug. Therefore, we hope our work would provide rational and timely help for developing anti-SARS-CoV-2 drugs.
Keywords: COVID-19; Covalent inhibitors; Drug repurpose; Drug screening; SCARdock.